These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1566498)

  • 1. Suppression of natural xenophile antibodies with the novel immunomodulating drug leflunomide.
    Ulrichs K; Kaitschick J; Bartlett R; Müller-Ruchholtz W
    Transplant Proc; 1992 Apr; 24(2):718-9. PubMed ID: 1566498
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term suppression of natural and graft-induced xenophile antibodies by short-term antigen-cyclophosphamide treatment.
    Breitkreuz A; Ulrichs K; Eckstein V; Müller-Ruchholtz W
    Transplant Proc; 1993 Feb; 25(1 Pt 1):416-8. PubMed ID: 8438359
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of leflunomide on T-independent xenoantibody formation in rats receiving hamster heart xenografts.
    Lin Y; Vandeputte M; Waer M
    Transplant Proc; 1996 Apr; 28(2):952. PubMed ID: 8623477
    [No Abstract]   [Full Text] [Related]  

  • 4. Down-regulation of xenophile antibodies by 15-deoxyspergualin in an experimental animal model.
    Ulrichs K; Wang H; Müller-Ruchholtz W
    Transplant Proc; 1994 Apr; 26(2):994-6. PubMed ID: 8171724
    [No Abstract]   [Full Text] [Related]  

  • 5. Mechanism of leflunomide-induced prevention of xenoantibody formation and xenograft rejection in the hamster to rat heart transplantation model.
    Lin Y; Sobis H; Vandeputte M; Waer M
    Transplant Proc; 1995 Feb; 27(1):305-6. PubMed ID: 7879012
    [No Abstract]   [Full Text] [Related]  

  • 6. Sustained suppression of xenoreactive natural antibodies: anti-IgM monoclonal antibody and anti-B cell immunosuppressants.
    Van der Werf WJ; Blakely ML; Hancock W; Soares M; Latinne D; Bazin H; Bach FH
    Transplant Proc; 1994 Jun; 26(3):1372-3. PubMed ID: 8029945
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunosuppression with leflunomide and cyclosporine prevents pig-to-rat islet xenograft rejection.
    Wennberg L; Wallgren AC; Sundberg B; Rafael E; Zhu S; Liu J; Tibell A; Karlsson-Parra A; Groth CG; Korsgren O
    Transplant Proc; 1995 Dec; 27(6):3314-5. PubMed ID: 8539967
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-B cell agents: suppression of natural antibodies and prolongation of survival in discordant xenografts.
    Blakely ML; Van der Werf WJ; Dalmasso AP; Bach FH
    Transplant Proc; 1994 Jun; 26(3):1374-5. PubMed ID: 8029946
    [No Abstract]   [Full Text] [Related]  

  • 9. Leflunomide-mediated tolerance of B lymphocytes for T-independent xenoantigens needs the presence of these xenoantigens.
    Lin Y; Vandeputte M; Waer M
    Transplant Proc; 1997; 29(1-2):1304. PubMed ID: 9123317
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term xenograft survival and suppression of xenoantibody formation in the hamster-to-rat heart transplant model using a combination therapy of leflunomide and cyclosporine.
    Lin Y; Sobis H; Vandeputte M; Waer M
    Transplant Proc; 1994 Dec; 26(6):3202. PubMed ID: 7998115
    [No Abstract]   [Full Text] [Related]  

  • 11. Mizoribine inhibits natural antibody production in a discordant xenograft model.
    Flores HC; Leventhal JR; Gruber SA; Schaffer MM; Bolman RM; Matas AJ
    Transplant Proc; 1992 Apr; 24(2):717. PubMed ID: 1566497
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of natural antibody production by a combination of 15-deoxyspergualin, mizoribine, cyclophosphamide, and splenectomy.
    Leventhal JR; Flores HC; Gruber SA; Matas AJ; Bolman RM
    Transplant Proc; 1992 Apr; 24(2):687. PubMed ID: 1566481
    [No Abstract]   [Full Text] [Related]  

  • 13. Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of mononuclear cells in rheumatoid arthritis.
    Dimitrijevic M; Bartlett RR
    Transplant Proc; 1996 Dec; 28(6):3086-7. PubMed ID: 8962195
    [No Abstract]   [Full Text] [Related]  

  • 14. In vivo mechanism of action of leflunomide: selective inhibition of the capacity of B lymphocytes to make T-independent xenoantibodies.
    Lin Y; Waer M
    Transplant Proc; 1996 Dec; 28(6):3085. PubMed ID: 8962194
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunosuppressive effects of leflunomide in a cardiac allograft model.
    Williams JW; Xiao F; Foster PF; Chong A; Sharma S; Bartlett R; Sankary HN
    Transplant Proc; 1993 Feb; 25(1 Pt 1):745-6. PubMed ID: 8438465
    [No Abstract]   [Full Text] [Related]  

  • 16. Synergistic activity of malononitrilamides with cyclosporine to control and reverse xenograft rejection.
    Schorlemmer HU; Kurrle R
    Int J Tissue React; 1997; 19(3-4):149-56. PubMed ID: 9506316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow-cytometric analysis of peripheral lymphocytes in the rat following penetrating keratoplasty and immunosuppressive treatment.
    Klebe S; Coupland SE; Krause L; Hoffmann F
    Ger J Ophthalmol; 1996 May; 5(3):137-45. PubMed ID: 8803575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leflunomide, a novel immunomodulatory agent: in vitro analyses of the mechanism of immunosuppression.
    Chong AS; Gebel H; Finnegan A; Petraitis EE; Jiang XL; Sankary HN; Foster P; Williams JW
    Transplant Proc; 1993 Feb; 25(1 Pt 1):747-9. PubMed ID: 8438466
    [No Abstract]   [Full Text] [Related]  

  • 19. Mechanism of action of leflunomide: in vivo uridine administration reverses its inhibition of lymphocyte proliferation.
    Silva HT; Cao W; Shorthouse R; Morris RE
    Transplant Proc; 1996 Dec; 28(6):3082-4. PubMed ID: 8962193
    [No Abstract]   [Full Text] [Related]  

  • 20. Modification of rat xenoantibodies with guinea pig liver antigen and pulse cyclophosphamide.
    Goldberg LC; Buckland EJ; Taube D
    Transplant Proc; 1994 Jun; 26(3):1276-8. PubMed ID: 8029907
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.